MiniMed Group
MiniMed Group's revenue rose 14.2% to $3.1 billion in fiscal 2026. Its operating margin was −6.1%, down from −5.4% a year earlier. Free cash flow was −$420 million. The diluted share count rose 1.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What MiniMed Group does
MiniMed makes devices and software for people with diabetes who need insulin several times a day. Its main product is an automated insulin delivery system: an insulin pump, a glucose sensor that reads blood sugar continuously, and software that adjusts the insulin dose every five minutes. It also sells a system for people who prefer injections, built around a smart insulin pen and a sensor, along with the supplies and apps that go with them.
MiniMed sells mainly through durable medical equipment suppliers in the United States, with a small share through pharmacies, and it sells in many countries abroad. Its customers are the patients, and doctors and nurses who prescribe its products. It says it competes with other makers of pumps and glucose sensors, and with companies that combine a partner's sensor with their own pump.
MiniMed was formerly part of Medtronic, which still holds a controlling stake. Medtronic has said it intends to give or sell the rest to its own shareholders later. The company has about 8,000 employees and runs two manufacturing facilities.
Its biggest risks, as it describes them
- Competition from other diabetes device makers, and price pressure on its products.
- Relying on sole suppliers, including one infusion-set supplier that received an FDA warning letter in January 2026.
- Failing to build higher-volume manufacturing lines for glucose sensors that meet its quality needs.
- Medtronic controls the company, and its plan to give up its remaining stake may not happen.
- Costs and difficulties of operating as a standalone public company after separating from Medtronic.
Income statement
MiniMed Group lost money in fiscal 2026: a net loss of $333 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash and short-term investments | 54 | 11 | 298 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | — | 1.3x | 1.9x |
| Quick ratio | — | 0.9x | 1.4x |
Cash flow
Projections
Project MiniMed Group's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of MiniMed Group reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 | FY26 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | 8.0% | 0.7% |
| Altman Z'' | 4.14 | 4.28 |
| Accruals ratio | — | −3.1% |
The nine F-score tests
| Test | FY25 | FY26 |
|---|---|---|
| Net income is positive | — | Fail |
| Cash from operations is positive | Pass | Fail |
| Return on assets rose | — | — |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | Pass |
| Share count didn't rise | Pass | Fail |
| Gross margin rose | Fail | Fail |
| Revenue rose relative to assets | — | — |
| F-score | — | — |
Compare
Put MiniMed Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| MiniMed Group | FY26 | 14.2% | −6.1% | −13.5% | — | — | — | |
| AdaptHealth | FY25 | −0.5% | 2.8% | 6.8% | 2.1% | 3.5x | 4 | Compare |
| Globus Medical | FY25 | 16.6% | 16.3% | 20.0% | 11.0% | −0.7x | 9 | Compare |
| Revvity | FY25 | 3.7% | 12.5% | 17.8% | 3.3% | 3.0x | 5 | Compare |
| Bruker | FY25 | 2.1% | 2.0% | 1.3% | 0.9% | 5.5x | 4 | Compare |
3 years of figures
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Income statement | |||
| Revenue | 2,469 | 2,715 | 3,102 |
| Revenue growth | — | 10.0% | 14.2% |
| Gross profit | 1,436 | 1,528 | 1,680 |
| Research and development | 437 | 436 | 448 |
| Operating income | −69 | −146 | −190 |
| Net income | −112 | −213 | −333 |
| Diluted EPS (US$) | −0.44 | −0.84 | −1.30 |
| Diluted shares (millions) | 253 | 253 | 257 |
| Cash flow | |||
| Cash from operations | 41 | 140 | −197 |
| Capital expenditure | 148 | 193 | 223 |
| Free cash flow | −107 | −53 | −420 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 38 | 41 | 46 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 54 | 11 | 298 |
| Debt incl. finance leases | — | — | — |
| Total assets | — | 4,201 | 4,630 |
| Total liabilities | — | 871 | 1,019 |
| Shareholders' equity | 3,448 | 3,330 | 3,611 |
| Margins and ratios | |||
| Gross margin | 58.2% | 56.3% | 54.2% |
| Operating margin | −2.8% | −5.4% | −6.1% |
| Net margin | −4.5% | −7.8% | −10.7% |
| Free cash flow margin | −4.3% | −1.9% | −13.5% |
| Rule of 40 (growth + FCF margin) | — | 8.0% | 0.7% |
| Return on capital | — | — | — |
| Return on equity | — | — | −9.6% |
| Return on assets | — | — | −7.5% |
| Net debt to EBITDA | — | — | — |